Press Releases.
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
January 27, 2021
-
December 01, 2020Definitive Agreement for $19.4 Million in Gross Proceeds
-
November 05, 2020First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")
-
November 02, 2020Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone
-
October 13, 2020Proceeds Used to Repay Debt Principal with Oxford Finance
-
August 13, 2020Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")
-
May 14, 2020Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
-
March 12, 2020FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326
-
December 16, 2019Regulus Plans to Re-Initiate Clinical Studies in Q1 2020
-
November 18, 2019
-
November 12, 2019Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326